Dr. Shih-Chieh Tsai
- Co-Founder, Chief Technology Officer & Head of Business, GEColl Biomedical Co., Ltd.
- Assistant Researcher, National Center of Biomodels (formerly National Laboratory Animal Center)
Dr. Tsai has over 20 years of R&D experience in genetic engineering and molecular biology. During his tenure at the National Center of Biomodels, he utilized gene editing technologies to develop over 60 mouse and rat animal models for academic and industrial research in Taiwan. He also contributed to the development of large-fragment gene editing techniques, which remain at the forefront of global technology.
While at GEColl Biomedical Co., Ltd., Dr. Tsai successfully developed a rat model expressing recombinant human collagen, and gained invaluable experience managing a startup from the ground up. He also led the establishment of the company’s CRO services, building a team and operational structure from scratch.
In 2025, Dr. Tsai co-founded CellBall Biomedical with COO Wei-Yu Lin, focusing on the integration of gene editing with 3D cell culture technologies. Their goal is to provide researchers in the biomedical field with a high-performance, stable, and cost-effective 3D cell culture platform and services.
Dr. Tsai and the CellBall Biomedical team envision applying the 3D cell culture system to personalized drug screening, offering patients and clinicians more precise treatment recommendations, reducing physiological burden, and enabling more efficient allocation of medical resources.
Wei-Yu Lin
- Associate Manager, GEColl Biomedical Co., Ltd.
- Senior Biochemical R&D Engineer, Delta Electronics
- Senior Technical Specialist, Body Organ Biomedical Corporation
Mr. Lin has over 12 years of experience in biomedical materials and tissue engineering.
During his tenure at Body Organ Biomedical Corporation, he was responsible for developing Class III medical grade bio-cornea medical-grade bio-ocular corneas, utilizing fish scale–based materials for bio-cornea research and establishing animal corneal transplantation models, in collaboration with clinical ophthalmologists for large-animal preclinical trials.
At GEColl Biomedical Co., Ltd., Mr. Lin developed humanized collagen raw materials in gene-edited rat models and obtained U.S. FDA Master Files for Devices (MAFs).
He also developed next-generation intelligent subcutaneous implants, supported by the Taiwan Ministry of Science and Technology’s Southern Smart Biomedical Cluster Program, with a total project budget of NT$6 million.
Furthermore, he developed 3D cell culture hydrogels for commercialization, applied in research products and cancer drug screening platforms, and has contributed to one utility model patent, two invention patents, and four invention patents Pending.